Video

ecancer's extensive video archive features interviews, panel discussions and conference coverage on almost every topic in oncology.

Darolutamide plus ADT provides deep and durable PSA responses in metastatic hormone-sensitive prostate cancer

Prof Fred Saad - University of Montreal Hospital Center, Montreal, Canada
Darolutamide plus ADT provides deep and durable PSA responses in metastatic hormone-sensitive prostate cancer ( Prof Fred Saad - University of Montreal Hospital Center, Montreal, Canada )
27 Mar 2025

Transperineal biopsy improves prostate cancer detection

Prof Richard Bryant - Churchill Hospital in Oxford, Oxford, UK
Transperineal biopsy improves prostate cancer detection ( Prof Richard Bryant - Churchill Hospital in Oxford, Oxford, UK )
26 Mar 2025

TAR-200 plus cetrelimab show encouraging outcomes for MIBC patients ineligible for standard cisplatin-based chemotherapy

Dr Sarah Psutka - University of Washington, Seattle, USA
TAR-200 plus cetrelimab show encouraging outcomes for MIBC patients ineligible for standard cisplatin-based chemotherapy ( Dr Sarah Psutka - University of Washington, Seattle, USA )
26 Mar 2025

EAU 2025: Updates in NMIBC

Dr Bernadett Szabados, Dr Félix Guerrero-Ramos, Dr Alexandra Masson-Lecomte and Dr Giuseppe Simone
EAU 2025: Updates in NMIBC ( Dr Bernadett Szabados, Dr Félix Guerrero-Ramos, Dr Alexandra Masson-Lecomte and Dr Giuseppe Simone )
25 Mar 2025

Enzalutamide with 5-ARI is safe for older patients with castration-sensitive systemic prostate cancer

Dr Sindhuja Kadambi - University of Rochester Medical Center, Rochester, USA
Enzalutamide with 5-ARI is safe for older patients with castration-sensitive systemic prostate cancer ( Dr Sindhuja Kadambi - University of Rochester Medical Center, Rochester, USA )
17 Mar 2025

Isatuximab with VRd can benefit newly diagnosed multiple myeloma transplant ineligible patients

Prof Robert Orlowski - University of Texas MD Anderson Cancer Center, Houston, USA
Isatuximab with VRd can benefit newly diagnosed multiple myeloma transplant ineligible patients ( Prof Robert Orlowski - University of Texas MD Anderson Cancer Center, Houston, USA )
11 Mar 2025

Higher visceral fat linked to reduced overall survival in older adults with newly diagnosed gastrointestinal malignancies

Dr Supriya Maheshwari - University of Alabama, Tuscaloosa, USA
Higher visceral fat linked to reduced overall survival in older adults with newly diagnosed gastrointestinal malignancies ( Dr Supriya Maheshwari - University of Alabama, Tuscaloosa, USA )
10 Mar 2025

Talazoparib and enzalutamide combination therapy shows significant benefit in treating mCRPC

Prof Neeraj Agarwal - University of Utah, Salt Lake City, USA
Talazoparib and enzalutamide combination therapy shows significant benefit in treating mCRPC ( Prof Neeraj Agarwal - University of Utah, Salt Lake City, USA )
5 Mar 2025

Mevrometostat and enzalutamide show improved outcomes compared to enzalutamide alone in mCRPC

Dr Michael Schweizer - University of Washington Fred Hutch Cancer Center, Seattle, Washington
Mevrometostat and enzalutamide show improved outcomes compared to enzalutamide alone in mCRPC ( Dr Michael Schweizer - University of Washington Fred Hutch Cancer Center, Seattle, Washington )
26 Feb 2025

ctDNA evaluation may play a prognostic role in stage III colon cancer treated with celecoxib

Dr Jonathan Andrew Nowak - Dana-Farber Cancer Institute, Boston, USA
ctDNA evaluation may play a prognostic role in stage III colon cancer treated with celecoxib ( Dr Jonathan Andrew Nowak - Dana-Farber Cancer Institute, Boston, USA )
26 Feb 2025

Time to metastasis after prostatectomy should not be used as a prognostic factor for metachronous mHSPC

Dr Nicolas Sayegh - UT Southwestern Medical Center, Dallas, USA
Time to metastasis after prostatectomy should not be used as a prognostic factor for metachronous mHSPC ( Dr Nicolas Sayegh - UT Southwestern Medical Center, Dallas, USA )
25 Feb 2025

Combining chemotherapy with cemiplimab for advanced penile cancer may serve as a viable first-line treatment option

Prof Amit Bahl - University Hospitals Bristol, Bristol, UK
Combining chemotherapy with cemiplimab for advanced penile cancer may serve as a viable first-line treatment option ( Prof Amit Bahl - University Hospitals Bristol, Bristol, UK )
24 Feb 2025